Christian Hageseth, founder of Green Man Cannabis and author of ‘Big Weed,’ gives a glimpse into the business side of the marijuana world.
Generic-drug company Mylan goes on the offensive to counter persistent speculation about a pending bid from Israeli rival Teva Pharmaceutical Industries.
U.S. stock futures are rising going into one of the busiest weeks of earnings season.
The positive phase I safety study was conducted using a CAR-T therapy from Novartis and the University of Pennsylvania.
New Keytruda data presented for the first time shows an overall response rate of 19% and a median duration of response exceeding one year in lung cancer patients.
Jim Cramer and Action Alerts PLUS Research Director Jack Mohr discuss why Actavis is severely undervalued and an extremely compelling healthcare investment at these levels.
Health care stocks are up 33% over the last 12 months, nearly doubling the return of the S&P 500.
U.S. stock futures are falling as oil prices bounced back off a 2015 high and as General Electric reports earnings.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Materialise, a provider of 3D printing solutions, saw a loss in 2014 even as revenue was strong, as it beefed up spending in R&D and sales and marketing initiatives.
Hedge Fund Manager Mark Yusko finds select opportunities in the U.S. market in healthcare, airlines and cruise lines, and technology stocks like Netflix (NFLX) and Priceline (PCLN).
Mylan's deal to buy Perrigo is taking another potential target off the block.
In which Musk learns how to put a happy spin on failure from biotech CEOs.
U.S. stock futures are heading downward as Etsy and Virtu Financial stocks will begin trading, and as Netflix reports a big user base.
UnitedHealth (UNH) beat earnings estimates and raised its expectations for the rest of the year.
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV